Atopic Dermatitis Therapeutics Market to Make Great Impact in Near Future by 2026

Wilmington, Delaware, United States, Transparency Market Research Inc.: Atopic dermatitis, a type of eczema, is the most common and long-term inflammatory skin condition. This chronic disease causes itchy and red skin. This condition is most common in children but can occur at any age. This skin condition is also known as atopic eczema or dermatitis. It is often accompanied by asthma or fever. Other types of eczema include hand eczema, dyshidrotic eczema, and contact eczema.

Read Report Overview -

Symptoms of atopic dermatitis include dry, red, and sketchy skin; rashes on the neck, face, scalp or cheeks; and rashes on elbows and knees. In adults, discolored skin is a symptom of atopic dermatitis. In the U.S., 31 million Americans suffer from eczema, out of which 17.8 million have atopic dermatitis. According to the American Academy of Dermatology, 90% of atopic dermatitis occurs in patients below five years of age.

The global atopic dermatitis therapeutics market is projected to expand at a rapid pace in the next few years. Atopic dermatitis impacts patients emotionally and physically. It is more than just a skin disease. Allergies, particularly food allergy plays an important role in driving the atopic dermatitis therapeutics market by bringing blaze of eczema skin rash in infants leading the atopic dermatitis.

The global population of patients with atopic dermatitis is likely to increase. The FDA recently approved a topical treatment for atopic dermatitis in the form of Eucrisa. It is effective in adults and children for treating mild to moderate atopic dermatitis. Certain other factors such as climactic conditions and usage of soaps and detergents are expected to drive the incidence of skin diseases. Awareness about skin diseases is estimated to increase.

Request Brochure of Report -

Novel therapies for the treatment of atopic dermatitis are anticipated to be innovated and adopted. These factors are likely to boost the global atopic dermatitis market. However, high cost of care is projected to hamper the global atopic dermatitis therapeutics market. Atopic dermatitis often leads to an increase in visits to hospitals or clinics. This further acts as an economic burden on patients, thereby limiting patient access. Moreover, side effects of atopic eczema drugs is a leading restraining factor for the atopic dermatitis global market.

The global atopic dermatitis therapeutics market can be segmented based on drug class, route of administration, distribution channel, and region. In terms of drug class, the global atopic dermatitis therapeutics market can be classified into steroids, antihistamines, topical antiseptics, topical immunomodualtors or topical calcineurin inhibitors, antibiotics, monoclonal antibodies, and others. Topical corticosteroids fall under the steroid drug class and are effectively used for atopic eczema.

Get COVID-19 Analysis on Atopic Dermatitis Therapeutics Market -

Based on route of administration, the global atopic dermatitis therapeutics market can be categorized into oral, topical, and others. The topical route of administration is faster and very effective in the treatment of atopic dermatitis. It is the standard form of treatment. In terms of distribution channel, the global atopic dermatitis therapeutics market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies.

Based on region, the global atopic dermatitis therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017. The region held a major market share due to an increase in patient population, rise in government investments in research & development, acceptance of novel atopic dermatitis medication, highly effective treatment, and effective reimbursement policies.

Make an Enquiry Before Buying -

The market in Asia Pacific is likely to expand at a rapid pace, due to an increase in the prevalence of atopic dermatitis, developing health care technology, and rise in health care expenditure. Increase in demand for quality and novel treatment methods in the region makes Asia Pacific an emerging region of the Germany and France are steadily increasing their investments in providing better health care solutions to patients with atopic dermatitis. This is expected to drive the market in Europe in the coming years.

Major players operating in the global atopic dermatitis therapeutics market are Regeneron, F. Hoffmann-La Roche Ltd., Encore Dermatology, Inc. , AbbVie, Inc., LEO Pharma A/S, Astellas Pharma Inc., Bausch Health , GlaxoSmithKline plc., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Nestlé Skin Health (Galderma) and others.

More Trending Reports by Transparency Market Research –

Erectile Dysfunction Drugs Market:

Regulatory Affairs Outsourcing Market:

Digital Health Market:

Equine Healthcare Market:

Stem Cells Market:

Medical Imaging Equipment Market:

Home Healthcare Market:

Triclabendazole Market:

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update -


Rohit Bhisey
Transparency Market Research Inc.
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453

Back to news